Literature DB >> 2342006

Prospective comparative study of cefotetan with piperacillin for prophylaxis against infection in elective colorectal surgery.

M J Hershman1, R I Swift, D T Reilly, W A Logan, J M Sackier, H Gompertz, J Horner, N W Baker, C B Wood.   

Abstract

This study compared one dose of cefotetan with three doses of piperacillin as prophylaxis against wound infection in 153 patients undergoing elective colorectal surgery. The patients were randomized into two groups: the first received 2 g cefotetan intravenously with induction of anaesthesia (n = 75), and the second received three doses of 2 g piperacillin (n = 78). Wound infection was defined as the presence of an abscess or discharging pus from the wound. In the cefotetan group there were 14 (19%) wound infections and 13 (17%) in the piperacillin group. There were three septic deaths, one in the cefotetan group and two in the piperacillin group. Both groups were comparable with regard to age, sex, nature of pathology and pre- and perioperative risk factors. No significant haematological or biochemical abnormalities were detected. The only adverse reaction was one patient who had an allergic reaction (rash) to piperacillin. These data suggest that single-dose cefotetan is as effective as triple-dose piperacillin in prophylaxis against infection in elective colorectal surgery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2342006

Source DB:  PubMed          Journal:  J R Coll Surg Edinb        ISSN: 0035-8835


  3 in total

1.  Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study.

Authors:  S K Saha
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

2.  Comparison of cefotaxime plus metronidazole versus cefoxitin for prevention of wound infection after abdominal surgery.

Authors:  L Kow; J Toouli; J Brookman; P J McDonald
Journal:  World J Surg       Date:  1995 Sep-Oct       Impact factor: 3.352

3.  Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.

Authors:  Fausto de Lalla
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.